Adding the HCV protease inhibitor simeprevir to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after 3 months, according to findings from the PROMISE study presented at the Digestive Disease Week meeting this week in Orlando.
http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/4119-ddw-2013-simeprevir-boosts-response-to-interferon-based-therapy-for-prior-relapsers
http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/4119-ddw-2013-simeprevir-boosts-response-to-interferon-based-therapy-for-prior-relapsers
No comments:
Post a Comment